Jennifer Whiting, PhD
About Jennifer Whiting, PhD
Jennifer Whiting, PhD, serves as the Associate Director of IVD Development at Predicine, where she focuses on advancing precision medicine through liquid biopsy diagnostic applications. With a strong background in pharmacology and extensive experience in the field, she has held various roles in research and development across multiple organizations.
Work at Predicine
Jennifer Whiting serves as the Associate Director of IVD Development at Predicine, a role she has held since 2022. In this position, she plays a collaborative and cross-functional role that supports internal IVD product development, pharmaceutical partnerships, and regulatory submissions. Her work focuses on advancing precision medicine, particularly through liquid biopsy diagnostic applications. She specializes in the validation of Predicine's next-generation sequencing (NGS) oncology assays for genomic profiling and biomarker detection.
Education and Expertise
Jennifer Whiting earned her Bachelor of Science degree in Biology from Rensselaer Polytechnic Institute, where she studied from 2005 to 2009. She then pursued her Doctor of Philosophy in Pharmacology at the University of Washington - School of Medicine, completing her studies from 2009 to 2012. Her educational background provides a strong foundation for her expertise in precision medicine and liquid biopsy diagnostics.
Background
Jennifer Whiting has a diverse professional background in the field of biomedical research and development. She began her career as an Independent Undergraduate Researcher at Rensselaer Polytechnic Institute from 2006 to 2009. She then interned at The Jackson Laboratory in 2008. Following her doctoral studies, she worked as a Postdoctoral Research Fellow at the University of Washington for six months in 2015-2016. Her career includes roles at Thermo Fisher Scientific and Foundation Medicine, where she contributed to companion diagnostics and CDx development operations.
Professional Experience
Jennifer Whiting has held several significant positions in the biotechnology sector. After her postdoctoral fellowship, she worked at Thermo Fisher Scientific as Associate Scientist II from 2016 to 2017 and later as Scientist III from 2017 to 2020. She transitioned to Foundation Medicine, where she served as Senior Scientist in Companion Diagnostics from 2020 to 2022 and briefly as Principal Scientist in CDx Development Operations in 2022. Her extensive experience in these roles has equipped her with a comprehensive understanding of IVD product development and regulatory processes.